{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:31:22Z","timestamp":1773351082352,"version":"3.50.1"},"reference-count":28,"publisher":"BMJ","issue":"2","funder":[{"name":"Associa\u00e7\u00e3o Portuguesa de Farmaceuticos Hospitalares","award":["Renata Barbosa was granted (no grant reference num"],"award-info":[{"award-number":["Renata Barbosa was granted (no grant reference num"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1136\/ejhpharm-2024-004340","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:20:24Z","timestamp":1744723224000},"page":"137-141","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Exposure to potentially harmful excipients in neonates admitted to intensive care units using compounded medicines"],"prefix":"10.1136","volume":"33","author":[{"given":"Renata","family":"Barbosa","sequence":"first","affiliation":[{"name":"Pharmacy Service, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Carla","family":"Sampaio","sequence":"additional","affiliation":[{"name":"Pharmacy Service, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Luisa","family":"Sousa","sequence":"additional","affiliation":[{"name":"Pharmacy Service, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Susana","family":"Fraga","sequence":"additional","affiliation":[{"name":"Pharmacy Service, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Pedro","family":"Soares","sequence":"additional","affiliation":[{"name":"Pharmacy Service, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), University of Minho School of Medicine, Braga, Portugal"},{"name":"ICVS 3B\u2019s Associate Laboratory, Guimaraes, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal"},{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Porto, Porto, Portugal, Porto, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2026022302200628000_33.2.137.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5409\/wjcp.v2.i1.1","article-title":"Neonates need tailored drug formulations","volume":"2","author":"Allegaert","year":"2013","journal-title":"World J Clin Pediatr"},{"key":"2026022302200628000_33.2.137.2","unstructured":"Committee for Medicinal Products for Human Use (CHMP) . Guideline on pharmaceutical development of medicines for paediatric use. 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},{"key":"2026022302200628000_33.2.137.3","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s11096-022-01478-5","article-title":"Development and evaluation of an assessment of the age-appropriateness\/inappropriateness of formulations used in children","volume":"44","author":"Duncan","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2026022302200628000_33.2.137.4","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/PTS.0000000000000646","article-title":"Observational Study of Drug Formulation Manipulation in Pediatric Versus Adult Inpatients","volume":"17","author":"Spishock","year":"2021","journal-title":"J Patient Saf"},{"key":"2026022302200628000_33.2.137.5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11096-022-01388-6","article-title":"An economic evaluation of vial sharing of expensive drugs in automated compounding","volume":"44","author":"Baan","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2026022302200628000_33.2.137.6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11096-020-00990-w","article-title":"Orodispersible films as a personalized dosage form for nursing home residents, an exploratory study","volume":"42","author":"Visser","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"2026022302200628000_33.2.137.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.01.006"},{"key":"2026022302200628000_33.2.137.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.05.004"},{"key":"2026022302200628000_33.2.137.9","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000065"},{"key":"2026022302200628000_33.2.137.10","first-page":"196","article-title":"European Study of Neonatal Exposure to Excipients (ESNEE)","volume":"7","author":"Graham","year":"2011","journal-title":"Infant"},{"key":"2026022302200628000_33.2.137.11","article-title":"Neonates exposed to excipients: concern about safety","volume":"7","author":"Cuzzolin","year":"2018","journal-title":"J Pediatr Neonatal Individ Med"},{"key":"2026022302200628000_33.2.137.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-014-2272-z"},{"key":"2026022302200628000_33.2.137.13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2431-12-136","article-title":"Hospitalised neonates in Estonia commonly receive potentially harmful excipients","volume":"12","author":"Lass","year":"2012","journal-title":"BMC Pediatr"},{"key":"2026022302200628000_33.2.137.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-016-0551-8","article-title":"Off-label use and harmful potential of drugs in a NICU in Brazil: a descriptive study","volume":"16","author":"de Souza","year":"2016","journal-title":"BMC Pediatr"},{"key":"2026022302200628000_33.2.137.15","doi-asserted-by":"crossref","DOI":"10.1186\/s40780-021-00208-9","article-title":"Potentially harmful excipients in neonatal medications: a multicenter nationwide observational study in Japan","volume":"7","author":"Saito","year":"2021","journal-title":"J Pharm Health Care Sci"},{"key":"2026022302200628000_33.2.137.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1200521","article-title":"Paraben exposure through drugs in the neonatal intensive care unit: a regional cohort study","volume":"14","author":"Iacobelli","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026022302200628000_33.2.137.17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010119","article-title":"Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units","volume":"16","author":"Bobillot","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026022302200628000_33.2.137.18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2020.1805431","article-title":"Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates","volume":"19","author":"Sridharan","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2026022302200628000_33.2.137.19","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-001107"},{"key":"2026022302200628000_33.2.137.20","first-page":"277","article-title":"Propylene glycol toxicity in children","volume":"19","author":"Lim","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026022302200628000_33.2.137.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)81183-4"},{"key":"2026022302200628000_33.2.137.22","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.565328"},{"key":"2026022302200628000_33.2.137.23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/0929-693X(96)81719-2","article-title":"Asthma and intolerance to benzoates","volume":"3","author":"Petrus","year":"1996","journal-title":"Arch Pediatr"},{"key":"2026022302200628000_33.2.137.24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0960327117718042","article-title":"Regulatory risk assessments: is there a need to reduce uncertainty and enhance robustness? Update on propylparaben in relation to its EU regulatory status","volume":"36","author":"Snodin","year":"2017","journal-title":"Hum Exp Toxicol"},{"key":"2026022302200628000_33.2.137.25","doi-asserted-by":"crossref","unstructured":"Barbosa R , Fraga S , Soares P , et al . Implementation of a strategy to overcome the potential toxic effects of propylene glycol in neonates. Eur J Hosp Pharm 2024:A39.2-A. doi:10.1136\/ejhpharm-2024-eahp.81","DOI":"10.1136\/ejhpharm-2024-eahp.81"},{"key":"2026022302200628000_33.2.137.26","unstructured":"Committee for Medicinal Products for Human Use (CHMP) . Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use. 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-use-methyl-and-propylparaben-excipients-human-medicinal-products-oral-use_en.pdf"},{"key":"2026022302200628000_33.2.137.27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/pthp-2018-0008","article-title":"Development and Preparation of Oral Suspensions for Paediatric Patients \u2013 a Challenge for Pharmacists","volume":"3","author":"Bruns","year":"2018","journal-title":"Pharm Technol Hosp Pharm"},{"key":"2026022302200628000_33.2.137.28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2012.11.001","article-title":"Two-round Delphi technique for the consensual design of a paediatric pharmaceutical care model","volume":"68","author":"Fern\u00e1ndez-Llamazares","year":"2013","journal-title":"Pharmacol Res"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:20:34Z","timestamp":1771842034000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/ejhpharm-2024-004340"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004340","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}